Equities Analysts Offer Predictions for Neurocrine Biosciences, Inc.’s Q4 2022 Earnings (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating) – Analysts at Wedbush lowered their Q4 2022 earnings estimates for Neurocrine Biosciences in a research note issued on Monday, January 23rd. Wedbush analyst L. Chico now forecasts that the company will post earnings of $1.11 per share for the quarter, down from their previous forecast of $1.13. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $1.80 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q2 2023 earnings at $1.21 EPS, Q4 2023 earnings at $1.41 EPS, FY2023 earnings at $4.91 EPS and FY2027 earnings at $13.04 EPS.

Other equities research analysts have also issued reports about the stock. Royal Bank of Canada boosted their price objective on shares of Neurocrine Biosciences from $101.00 to $117.00 and gave the stock a “sector perform” rating in a report on Wednesday, November 2nd. JPMorgan Chase & Co. boosted their price objective on shares of Neurocrine Biosciences from $138.00 to $143.00 and gave the stock an “overweight” rating in a report on Thursday, November 3rd. Mizuho boosted their price objective on shares of Neurocrine Biosciences from $105.00 to $116.00 and gave the stock a “neutral” rating in a report on Wednesday, November 2nd. UBS Group started coverage on shares of Neurocrine Biosciences in a report on Tuesday, October 11th. They issued a “buy” rating and a $136.00 price objective for the company. Finally, Cantor Fitzgerald boosted their price objective on shares of Neurocrine Biosciences from $127.00 to $132.00 and gave the stock an “overweight” rating in a report on Wednesday, November 2nd. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $122.24.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $108.66 on Wednesday. Neurocrine Biosciences has a 1 year low of $72.28 and a 1 year high of $129.29. The firm has a market cap of $10.45 billion, a PE ratio of 190.63 and a beta of 0.54. The company has a 50 day simple moving average of $117.62 and a two-hundred day simple moving average of $110.20.

Neurocrine Biosciences (NASDAQ:NBIXGet Rating) last announced its earnings results on Tuesday, November 1st. The company reported $0.69 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.15). Neurocrine Biosciences had a net margin of 4.19% and a return on equity of 4.06%. The company had revenue of $387.90 million for the quarter, compared to the consensus estimate of $378.05 million.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Gary A. Lyons sold 15,000 shares of the business’s stock in a transaction on Monday, October 31st. The shares were sold at an average price of $114.76, for a total transaction of $1,721,400.00. Following the transaction, the director now directly owns 203,697 shares of the company’s stock, valued at approximately $23,376,267.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director Gary A. Lyons sold 15,000 shares of the company’s stock in a transaction dated Monday, October 31st. The shares were sold at an average price of $114.76, for a total value of $1,721,400.00. Following the sale, the director now directly owns 203,697 shares of the company’s stock, valued at approximately $23,376,267.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Benevich sold 400 shares of the company’s stock in a transaction dated Friday, January 6th. The stock was sold at an average price of $125.00, for a total transaction of $50,000.00. Following the completion of the transaction, the insider now owns 15,643 shares in the company, valued at approximately $1,955,375. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 139,534 shares of company stock valued at $17,059,059. 4.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of hedge funds have recently bought and sold shares of NBIX. Louisiana State Employees Retirement System lifted its stake in Neurocrine Biosciences by 1.2% during the 4th quarter. Louisiana State Employees Retirement System now owns 25,700 shares of the company’s stock valued at $3,070,000 after acquiring an additional 300 shares during the period. National Bank of Canada FI lifted its stake in Neurocrine Biosciences by 872.8% during the 4th quarter. National Bank of Canada FI now owns 11,129 shares of the company’s stock valued at $1,329,000 after acquiring an additional 9,985 shares during the period. Bank Julius Baer & Co. Ltd Zurich lifted its stake in Neurocrine Biosciences by 47.3% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 2,474 shares of the company’s stock valued at $295,000 after acquiring an additional 794 shares during the period. Toth Financial Advisory Corp bought a new position in Neurocrine Biosciences during the 4th quarter valued at about $858,000. Finally, Xponance Inc. lifted its stake in Neurocrine Biosciences by 6.7% during the 4th quarter. Xponance Inc. now owns 22,332 shares of the company’s stock valued at $2,667,000 after acquiring an additional 1,410 shares during the period. Institutional investors own 92.58% of the company’s stock.

About Neurocrine Biosciences

(Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

See Also

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.